ReviewCurrent hypertension reports2003
Aldosterone: a risk factor for vascular disease.
Review in Current hypertension reports, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.The Cochrane database of systematic reviews · 2020Pooled it
- [Aldosterone antagonists for preventing the progression of chronic kidney disease].Der Urologe. Ausg. A · 2016Trial
- Aldosterone Synthase Inhibitors for Cardiorenal Protection: Ready for Prime Time?Kidney & blood pressure research · 2024Review
- Comparisons of skin microvascular changes in patients with primary aldosteronism and essential hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2020Article
- Proinflammatory/profibrotic effects of aldosterone in Gitelman's syndrome, a human model opposite to hypertension.Journal of endocrinological investigation · 2019Article
- Atorvastatin inhibits pro-inflammatory actions of aldosterone in vascular smooth muscle cells by reducing oxidative stress.Life sciences · 2019Article
- Perioperative management of patient with Conn's syndrome and severe hypokalaemia: How low is too low?Indian journal of anaesthesia · 2019Article
- Renal inflammation and elevated blood pressure in a mouse model of reduced {beta}-ENaC.American journal of physiology. Renal physiology · 2011Article
- A comprehensive review of the clinical aspects of primary aldosteronism.Nature reviews. Endocrinology · 2011Review
- Diagnosis and treatment of primary aldosteronism.Reviews in endocrine & metabolic disorders · 2011Review
- Oxidative stress-related proteins in a Conn's adenoma tissue. Relevance for aldosterone's prooxidative and proinflammatory activity.Journal of endocrinological investigation · 2010Article
- Is the vascular endothelium under the control of aldosterone? Facts and hypothesis.Pflugers Archiv : European journal of physiology · 2007Review
- Endothelial Vascular Function in Hypertensive Patients After Renin-Angiotensin System Blockad.Journal of clinical hypertension (Greenwich, Conn.) · 2006Article
- Low-renin hypertension with relative aldosterone excess is associated with impaired NO-mediated vasodilation.Hypertension (Dallas, Tex. : 1979) · 2005Article
- Mesenteric artery remodeling and effects of imidapril and irbesartan on it in spontaneously hypertensive rats.World journal of gastroenterology · 2004Article
- Development of [Nuclear medicine and biologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Blockade of the renin-angiotensin-aldosterone system with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor antagonists has resulted in beneficial effects in essential hypertensive patients. However, occurrence of cardiovascular events has not been appropriately controlled beyond a certain percentage. One reason could be the effects of aldosterone, the final component of the system. The aldosterone escape phenomenon could explain undesirable outcomes observed in hypertensive patients even under treatment with ACE inhibitors or angiotensin antagonists. Aldosterone has direct effects on the vasculature and has been associated with vascular smooth muscle cell hypertrophy, endothelial dysfunction, cardiac fibrosis, proteinuria, and renal vascular injury. Animal models and clinical trials have proven the benefit of aldosterone receptor antagonism. With increased recognition of the prevalence of hyperaldosteronism in patients thought to have "essential" hypertension, the use of drugs that block aldosterone action may become more widespread and protect the vasculature from the deleterious effects of aldosterone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.